We are live on ! Find out more
PVLA

Palvella Therapeutics
PVLA

90 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2017 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 6

69% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 16

37% more capital invested

Capital invested by funds: $130M → $179M (+$48.6M)

36% more funds holding

Funds holding: 66 → 90 (+24)

0.02% more ownership

Funds ownership: 0.64% → 0.66% (+0.02%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

83% less call options, than puts

Call options by funds: $27K | Put options by funds: $156K

Holders
90
Holders Change
+24
Holders Change %
+36.36%
% of All Funds
2.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
30
Increased
27
Reduced
16
Closed
6
Calls
$27K
Puts
$156K
Net Calls
-$129K
Net Calls Change
-$34K

Top Buyers

1
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$2.59M
2
AL
AJO LP
Pennsylvania
+$1.7M
3
Millennium Management
Millennium Management
New York
+$1.49M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.47M
5
VIA
Vident Investment Advisory
Georgia
+$1.22M

Top Sellers

1
TCM
Tekla Capital Management
Massachusetts
-$5.09M
2
BI
BVF Inc
California
-$2.11M
3
OFM
Omega Fund Management
Massachusetts
-$1.74M
4
SFM
Sphera Funds Management
Israel
-$1.16M
5
EI
EAM Investors
California
-$348K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$54.8M – – –
BI
2
BVF Inc
California
$19.8M -$2.11M -4,537 -12%
TCM
3
Tekla Capital Management
Massachusetts
$14.8M -$5.09M -10,940 -31%
BlackRock
4
BlackRock
New York
$12.1M +$395K +849 +4%
OFM
5
Omega Fund Management
Massachusetts
$6.83M -$1.74M -3,750 -25%
SFM
6
Sphera Funds Management
Israel
$6.04M -$1.16M -2,500 -20%
Millennium Management
7
Millennium Management
New York
$5.28M +$1.49M +3,208 +58%
SSA
8
Schonfeld Strategic Advisors
New York
$5.1M -$291K -625 -7%
LOAMU
9
Lombard Odier Asset Management (USA)
New York
$5.08M – – –
Renaissance Technologies
10
Renaissance Technologies
New York
$4.91M +$1.47M +3,162 +64%
State Street
11
State Street
Massachusetts
$4.01M +$84.1K +181 +3%
Arrowstreet Capital
12
Arrowstreet Capital
Massachusetts
$3.37M +$2.59M +5,580 New
Northern Trust
13
Northern Trust
Illinois
$2.4M -$16.3K -35 -0.9%
AL
14
AJO LP
Pennsylvania
$2.21M +$1.7M +3,664 New
TCIM
15
TIAA CREF Investment Management
New York
$2.06M +$318K +684 +25%
Morgan Stanley
16
Morgan Stanley
New York
$2.01M +$259K +557 +20%
Goldman Sachs
17
Goldman Sachs
New York
$1.98M +$944K +2,030 +163%
BIM
18
Bogle Investment Management
Massachusetts
$1.95M +$249K +535 +20%
AQR Capital Management
19
AQR Capital Management
Connecticut
$1.85M +$1M +2,159 +238%
VIA
20
Vident Investment Advisory
Georgia
$1.59M +$1.22M +2,632 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$1.51M +$582K +1,252 +100%
Deutsche Bank
22
Deutsche Bank
Germany
$1.31M +$644K +1,386 +177%
Cerity Partners
23
Cerity Partners
New York
$1.21M – – –
Acadian Asset Management
24
Acadian Asset Management
Massachusetts
$877K +$82.8K +178 +14%
Vanguard Group
25
Vanguard Group
Pennsylvania
$860K +$51.1K +110 +8%
1
2 3 4

PVLA Hedge Fund Activity: Q4 2017 in Review

90 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2017, worth a combined $179M — up 37% from $130M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new PVLA positions and 6 closed out — a net gain of 24 holders — while 27 added to existing stakes and 16 trimmed.

The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $2.59M. The largest seller was Tekla Capital Management, cutting an estimated $5.09M.

  • 90 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2017, up from 66 in Q3 2017.
  • Funds reported $179M of Palvella Therapeutics stock for Q4 2017, up 37% quarter-over-quarter.
  • 30 funds opened new Palvella Therapeutics positions in Q4 2017 and 6 closed out, a net change of +24 holders.
  • The largest Palvella Therapeutics buyer in Q4 2017 was Arrowstreet Capital, an estimated $2.59M added.
  • The largest Palvella Therapeutics seller in Q4 2017 was Tekla Capital Management, an estimated $5.09M sold.

Based on aggregated 13F filings for Q4 2017.